248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi(Yale University), Sibylle J. Hauske(Heidelberg University), Jyothis T. George(Boehringer Ingelheim (China)), Michaela Mattheus(Boehringer Ingelheim (Germany)), Bernard Zinman(Mount Sinai Hospital), Maximilian von Eynatten(Nestlé (Switzerland)), Christoph Wanner(Universitätsklinikum Würzburg)
Cited by 0
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
|Diabetes Care|2012|3.2k